Staff Writer

An analysis of the DCCT and EDIC studies provides clinicians with insights into the risk factors associated with incident cancer diagnoses among patients with type 1 diabetes.

New research adds more evidence against the supplement's efficacy in preventing fractures.

Third annual report from Optavise demonstrates why ongoing health benefits education is critical.

An analysis of nationally representative data from NHANES cycles from 1999-2000 through 2017-2018 suggests just 6.8% of US adults had optimal cardiometabolic health.

An analysis of real-world data from more than 6500 patients compared the risk of fracture for insulin, metformin, and a combination of insulin and metformin.

An analysis of the SEARCH for Youth in Diabetes describes historic and contemporary disparities in insulin pump use for pediatric type 1 diabetes based on racial/ethnic background, household income, and insurance type.

Research indicates use of the SGLT2 inhibitor could reduce risk of developing kidney stones

A new report from the CDC that examined 20-year trends in vision impairment among patients with diabetes, which suggests the rate of decline in vision impairment began to plateau in 2012 and may be on the rise in recent years.

The FreeStyle Libre 3 system, billed as the world's smallest, thinnest, and most accurate 14-day glucose sensor, received FDA clearance on May 31 and is expected to be available in participating pharmacies later this year.

Using 21 years of follow-up data from more than 3000 patients with prediabetes, results of the DPPOS study demonstrate metformin use and lifestyle intervention reduced the risk of progressing to T2D, but did little to reduce the long-term risk of cardiovascular disease in these patients.

A systematic review and meta-analysis of 7 trials provide a detailed overview of the reductions in HbA1c and body weight, as well as the safety, of tirzepatide in various doses compared against placebo and other diabetes medications from clinical trials.

A retrospective analysis of more than 25k patients with type 2 diabetes details the impact achieving early glycemic control can have on the risk of cardiovascular disease events among these patients.

Announced on May 13, the approval indicates Eli Lilly and Company's novel dual GLP-1/GIP agonist, tirzepatide (Mounjaro), for use as an adjunct to diet and exercise to improve blood sugar in adult patients with type 2 diabetes.